CLINICAL TRIAL / NCT04060849

Inclusion Criteria: - Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease - English speaking - Capable of providing informed consent - Planned to receive follow-up at the transplant site for the first 100 days post transplantation - Subjects who the investigator believes can and will comply with the study protocol Exclusion Criteria: - Documented respiratory viral infection in the two weeks prior to enrollment - Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine) - Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E) - Receiving oxygen supplementation at time of enrollment - Active mucositis at time of enrollment - Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule - Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids) - Unable to complete study procedures (e.g. nasal swab self-testing)